[Comparison of cost-effectiveness and efficacy of selected inhaled steroids in asthma treatment from budget perspective].
Due to limited resources, when choosing among available treatment opportunities, it is necessary to include results of pharmaco-economic assessments. The aim of this study was to compare cost-effectiveness of Pulmicort Turbuhaler and Flixotide Rotadisc in asthma treatment. Result of randomised clinical study reported in Great Britain was used as a source of efficacy data. Costs of compared treatment options were calculated using the difference between full pharmacy price and patient's co-payment of consumed pharmaceuticals, as recorded in Warsaw open pharmacy shop in May 1999. It has been shown, statistically significant difference of cost-effectiveness in favour of Pulmicort Turbuhaler.
Szkultecka-Debek
M
M
Astra Pharmaceuticals Poland Sp. z o.o.
Szamotulska
K
K
Kułaga
Z
Z
D000280:Administration, Inhalation; D000287:Administration, Topical; D000893:Anti-Inflammatory Agents / Q000191:economics* / Q000627:therapeutic use*; D001249:Asthma / Q000188:drug therapy* / Q000191:economics*; D003362:Cost-Benefit Analysis; D005938:Glucocorticoids; D006801:Humans; D016896:Treatment Outcome
D000893:Anti-Inflammatory Agents; D005938:Glucocorticoids